PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) has scheduled a conference call on June 2 at 8:30am EST to discuss results of first phase clinical studies for the investigational anesthetic agent, ABP-700, and the investigational lipid-modulating agent, MDCO-216. Summary results for ABP-700 were presented at the Dutch Society of Anesthesiology in Maastricht, Netherlands, while results for MDCO-216 were presented at the 17th International Symposium on Atherosclerosis in Amsterdam, Netherlands.
Help employers find you! Check out all the jobs and post your resume.
